- The stock price of Heat Biologics Inc (NASDAQ: HTBX) increased by 40.15%. This is why it happened.
The stock price of Heat Biologics Inc (NASDAQ: HTBX) increased by 40.15% as it went from $6.85 to $9.60. Investors are responding positively to the company filing for a patent application called “GP96-Based Cancer Therapy.”
“The present disclosure relates, inter alia, to compositions and methods for treating cancer, including lung cancer (e.g., Non-Small Cell Lung Cancer), comprising administering (a) a cell harboring an expression vector comprising a nucleotide sequence that encodes a secretable vaccine protein and (b) an immune checkpoint inhibitor to a subject in need thereof,” says the patent abstract.
About a week ago, Heat Biologics announced that Dr. Roger B. Cohen, MD, Professor of Medicine at the University of Pennsylvania Perelman School of Medicine, presented an overview of the latest HS-110 data at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting which was held from June 4-8, 2021.
HS-110 — in combination with a checkpoint inhibitor (CPI) — is a potentially transformational agent to improve survival benefit for patients with non-small cell lung cancer (NSCLC). And it is a first-in-class, allogeneic, off-the shelf cell-based therapy developed by Heat leveraging its proprietary gp96 platform.
“This data further reinforces the potential utility of HS-110 in combination with a CPI for multiple treatment settings of NSCLC. The growing body of clinical data demonstrates that HS-110 in combination with a CPI is well tolerated and has the potential to enhance survival benefit when given with a CPI. Our latest results, consistent with previously reported data, provide a strong foundation for the Company to discuss possible Phase 3 registration trial designs with the FDA and potential partners,” said Jeff Wolf, CEO of Heat in a statement last week.
Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.
